Yearly Archives: 2013

Fireworks and heated debate were expected by many when Robert Whitaker recently addressed a group at the National Alliance on Mental Illness (NAMI) annual convention in San Antonio, Texas. So why was Whitaker invited to the national NAMI convention and how did it turn out?

Just as the American Psychiatric Association's (APA) long-delayed DSM5 was about to launch, the director of NIMH, Dr Thomas Insel, provoked a flurry of acrimony when he mentioned in his blog that his organisation intended to move away from the ideas behind DSM: “Patients with mental disorders deserve better... NIMH will be re-orienting its research away from DSM categories... we will be supporting research projects that look across current categories – or sub-divide current categories – to begin to develop a better system”. It now seems Insel's comments had more to do with NIMH funding needs than points of principle.

Jock McLaren is an Australian psychiatrist who worked 25yrs in the remote north of the country. He occupies himself delving into the philosophical basis...

I got a call from a colleague – someone with whom I’ve worked fairly closely over these past six years. The problem was the typical reaction one can expect when you bring together people in clinical and a variety of other roles who have been indoctrinated to think that medication is the way, and you offer clear and direct challenges to their belief system. Many people (most, even) responded well to the workshop. Some did not.

In this blog, I discuss three RCTs that support Martin Harrow's findings in his naturalistic study that long term use of neuroleptics is associated with worse functional outcomes.

If your government espouses freedom for all but abuses citizens of its own as well other countries, its pronouncements are pure propaganda. This article seeks to help readers make the connection between the public and secret behaviors of the U.S. government as it continues to oppress those individuals within its reach that occupy a politically marginalized status; including, of course, persons who are survivors and/or users of psychiatric services.

On June 12th, Psychology Today published an article entitled, "Benzo Hysteria: the Chilling Effects of the 'Addictive' label," by Ed Shorter, PhD. A dangerous and unfounded claim was made in its final paragraph, which reads as follows: "The benzos are among the safest and most effective drug classes in the history of psychopharmacology." Benzodiazepines are in fact highly addictive and many people suffer for years from protracted withdrawal syndromes that are disabling.

This video from Bipolarwakingup.com explores why what most people think about the relationship between genetics, chemical imbalance theory and bipolar disorder is pure myth.

Nev Jones is a doctoral student interested in the intersections of psychiatry, psychology, philosophy, neuroscience and "mad" studies. She is co-director of Chicago Hearing...

Users & Survivors in Academia (USA) is a support, advocacy, and resource-sharing group for graduate students (both master’s and doctoral) with psychiatric disabilities or current/past experience in the behavioral health system. USA started primarily for us to reach our peers across the country and engage in mutual support and advocacy around issues we face in higher education settings. Over the past year, USA has grown to 30 members in states across the country, and has quickly evolved into a forum to organize individual and systems advocacy, and support one another in self-advocacy in our own academic institutions.

When we look closely at the current mainstream diagnostic and support system for so-called mental disorders today, the utter absurdity of it quickly becomes apparent. We have a system composed of literally hundreds of discrete “mental disorders” (those listed in the DSM), all of which are believed to be the direct result of soon to be discovered brain diseases, in spite of the fact no reliable biomarkers have yet been found for any of them after a century of intense searching, a fact acknowledged just last month by the current designer-in-chief of this system himself.

Any time you create a word that only has meaning in a very specific context and then you start quite literally referring to people as if they were that word, you create more barriers to them moving beyond that context and on with their own life. Sure, it might feel good for a while. It might feel like you finally ‘belong’ somewhere. But what does that mean for your future?

It’s hard not to be enraged when your life is in shambles, you want nothing more than to get it back (and it’s happening barely, slowly, if at all), and you feel betrayed by the very people who you thought, at least at one point, meant to help you.

A study published today in the American Medical Association's journal JAMA Psychiatry reports that patients whose antipsychotic treatment was reduced or discontinued (DR) experienced a recovery...

I am constantly around people who build their lives around negative beliefs. More specifically, I am around people that build their lives around being “broken” because of something they identify as being a “brain disease.” It breaks my heart to hear the way people view themselves.

We work with one-size-fits-all interventions and reduce patients to their indication, or diagnosis. We tell ourselves that the algorithm works when it is “evidence-based”. What does this mean when we see that the house of cards has been glued into its position?

Opening his presentation, "The Case for Selected Use of Anti-Psychotics", at the national convention of the National Alliance for the Mentally Ill in San Antonio,...

Written by a committee including Jay Neugeboren, Michael B. Friedman, and an actual doctor, the D-MOM parodies the "Bible of Psychiatry" promises to "enable...

Dopamine supersensitivity as a result of sustained antipsychotic treatment can lead to compulsive drug seeking and drug-taking behavior, according to the theory offered by...

The New York Times offers the story of Dr. Peter Doshi, whose efforts to force pharmaceutical companies to open the records of their drug...

Another from the indefatigable Monica Cassani, on a theme close to the heart of this website: working with and through anger. Thank you, Monica. Beyond Meds →  

There is a class of “naturalistic” research that can only be conducted if the researcher happens to be in the “right” place at the “right” time. Julia Rucklidge was running clinical trials using micronutrients to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in adults when major earthquakes hit New Zealand. She and her research team contacted all current and past participants to establish whether they were taking micronutrients and for how long, and then they assessed how anxious, depressed and stressed people were one and two weeks post-quake. The results were revealing.

The New York Times tells the story of Matthew Knock, director of Harvard University's Laboratory for Clinical and Developmental Research, who recently received a...

We find ourselves in very interesting times with regard to our understanding of mental health. We find ever more heated, passionate and polarized discussions taking place with regard to the so-called mental disorders — how or even whether to try to classify them, which factors are generally helpful in recovery vs. which factors are generally harmful, what does “mental disorder” or “mental illness” even mean, and what does “recovery” even mean. Given the way my own mind works, I find it helpful, when such conundrums appear, to try to take the issues all the way down to the most fundamental assumptions and experiences that give rise to them, and then try to reconstruct an understanding that is more conducive to meeting our needs. This discussion, then, is an attempt to do just that.

Research by Andreasen et al. published in American Journal of Psychiatry in June of 2013 reported that the dosage of antipsychotic medication correlated with the reduction in the cortex volume; higher dosage was associated with greater reduction. In that same article, the authors suggested that, since they found brain shrinkage correlated with duration of relapse, curtailing or preventing the relapse would probably decrease damage. Their suggested mechanism for shortening the relapse process was to prescribe more drugs. Before advising fellow physicians to increase the dosage of antipsychotic drugs to prevent brain volume reduction, it is important to show the following: first, demonstrate that symptoms, in fact, reflect the occurrence of a damaging process; second, demonstrate that any treatment intervention actually targets the damaging process itself and not just the downstream symptoms of this process.